Harbor MedTech, a commercial-stage regenerative medicine company delivering innovative biologic wound-healing products, today announced that it won the LaunchPad competition at OCTANe’s 11th Annual Medical Device & Investor Forum, one of the largest medical device industry conferences in Southern California.
Harbor MedTech is developing innovative tissue regeneration products from biologic sources for chronic wounds, as well as for hernia and joint repair. Architect®, the company’s first product using its BriDGE® tissue regeneration technology, is a collagen matrix that heals chronic skin wounds faster compared to other skin substitutes.
Harbor MedTech was one of nine life science companies selected to present their business plans—more than 40 companies applied. Judges, who included venture capitalists, investment bankers, and corporate venture group representatives among others, evaluated the companies based on commercial, technical, and financial viability.
“We are excited to win OCTANe’s LaunchPad competition,” said Jerry Mezger, Harbor MedTech’s CEO and president. “The award is recognition of our pioneering regenerative medicine technology and our commercial progress based on recent equity funding and study results that support the wound-healing capabilities of Architect. October was a ‘month of milestones’ for Harbor MedTech, and we are committed to keeping the momentum going.”
“The judges felt that Harbor MedTech’s business plan answered many potential investor questions, including a product that addresses a clear medical need backed by a solid IP portfolio, FDA clearance, and leadership team,” said Paul Symczak, vice president of entrepreneurship at OCTANe, and executive director of the LaunchPad Small Business Development Center. “Jerry Mezger made a compelling presentation of Harbor MedTech’s attributes that won the day. The LaunchPad team congratulates Jerry and the company.”
LaunchPad is OCTANe's hands-on accelerator for start-ups that connects companies with resources and capital. As winner of the competition, Harbor MedTech will receive professional services valued at $135,000 from OCTANe partners, including branding and marketing communications services and intellectual property assessment. OCTANe’s Medical Device & Investor Forum was held Oct. 27–28, 2016, in Irvine, Calif.
About Harbor MedTech
Harbor MedTech, Inc., is a commercial-stage regenerative medicine company that has pioneered a new technology platform for biologic wound healing products needed to address chronic skin wounds such as diabetic foot ulcers and vascular ulcers, which remain a serious healthcare issue and cost billions of dollars a year. Healing these wounds in a timely manner is of paramount importance because the duration of ulceration correlates with increased rates of infection, amputation, and even death.
The company’s BriDGE® platform is a major leap forward in tissue regeneration—offering exceptional performance, proven clinical results, and an excellent economic advantage. Architect®, the company’s first BriDGE-based product, has been shown to heal chronic skin wounds with just one application—versus the multiple applications required with other collagen-based skin substitutes. Recent studies demonstrate that it may act by stimulating the patient’s own immune system to accelerate healing. Harbor MedTech was founded in 2010 and is based in Irvine, Calif. For information visit www.harbormedtech.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161101006813/en/Business Wire
Last updated on: 01/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.